{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:15:13Z","timestamp":1790745313735,"version":"4.1.0"},"reference-count":70,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,1,9]],"date-time":"2022-01-09T00:00:00Z","timestamp":1641686400000},"content-version":"unspecified","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,11,1]]},"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Soft-tissue sarcomas (STSs) are heterogeneous and aggressive tumors, with high metastatic risk. The immunologic constant of rejection (ICR) 20-gene signature is a signature of cytotoxic immune response. We hypothesized that ICR might improve the prognostic assessment of early-stage STS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively applied ICR to 1455 non-metastatic STS and searched for correlations between ICR classes and clinicopathological and biological variables, including metastasis-free survival (MFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-four per cent of tumors were classified as ICR1, 27% ICR2, 24% ICR3, and 15% ICR4. These classes were associated with patients\u2019 age, pathological type, and tumor depth, and an enrichment from ICR1 to ICR4 of quantitative\/qualitative scores of immune response. ICR1 class was associated with a 59% increased risk of metastatic relapse when compared with ICR2-4 class. In multivariate analysis, ICR classification remained associated with MFS, as well as pathological type and Complexity Index in Sarcomas (CINSARC) classification, suggesting independent prognostic value. A prognostic clinicogenomic model, including the three variables, was built in a learning set (n=339) and validated in an independent set (n=339), showing greater prognostic precision than each variable alone or in doublet. Finally, connectivity mapping analysis identified drug classes potentially able to reverse the expression profile of poor-prognosis tumors, such as chemotherapy and targeted therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>ICR signature is independently associated with postoperative MFS in early-stage STS, independently from other prognostic features, including CINSARC. We built a robust prognostic clinicogenomic model integrating ICR, CINSARC, and pathological type, and suggested differential vulnerability of each prognostic group to different systemic therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2021-003687","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T03:30:10Z","timestamp":1641871810000},"page":"e003687","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03805022","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04307277","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Francois","family":"Bertucci","sequence":"first","affiliation":[{"name":"Laboratory of Predictive Oncology, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), Institut Paoli-Calmettes, Aix-Marseille Universit\u00e9, INSERM UMR1068, CNRS UMR725, Marseille, France"},{"name":"Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France"},{"name":"French Sarcoma Group, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9627-7335","authenticated-orcid":false,"given":"Vincent","family":"Niziers","sequence":"additional","affiliation":[{"name":"Laboratory of Predictive Oncology, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), Institut Paoli-Calmettes, Aix-Marseille Universit\u00e9, INSERM UMR1068, CNRS UMR725, Marseille, France"},{"name":"Department of Surgery, Institut Paoli-Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"de Nonneville","sequence":"additional","affiliation":[{"name":"Laboratory of Predictive Oncology, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), Institut Paoli-Calmettes, Aix-Marseille Universit\u00e9, INSERM UMR1068, CNRS UMR725, Marseille, France"},{"name":"Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2674-3123","authenticated-orcid":false,"given":"Pascal","family":"Finetti","sequence":"additional","affiliation":[{"name":"Laboratory of Predictive Oncology, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), Institut Paoli-Calmettes, Aix-Marseille Universit\u00e9, INSERM UMR1068, CNRS UMR725, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9na","family":"Mescam","sequence":"additional","affiliation":[{"name":"French Sarcoma Group, Lyon, France"},{"name":"Department of Pathology, Institut Paoli-Calmettes, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Mir","sequence":"additional","affiliation":[{"name":"French Sarcoma Group, Lyon, France"},{"name":"Department of Medical Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8540-5351","authenticated-orcid":false,"given":"Antoine","family":"Italiano","sequence":"additional","affiliation":[{"name":"French Sarcoma Group, Lyon, France"},{"name":"Department of Medical Oncology, Institut Bergonie, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Le Cesne","sequence":"additional","affiliation":[{"name":"French Sarcoma Group, Lyon, France"},{"name":"Department of Medical Oncology, Gustave Roussy, Villejuif, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-120X","authenticated-orcid":false,"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[{"name":"French Sarcoma Group, Lyon, France"},{"name":"Department of Medical Oncology, Centre Leon Berard, Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Ceccarelli","sequence":"additional","affiliation":[{"name":"DIETI, University of Naples Federico II Faculty of Engineering, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bedognetti","sequence":"additional","affiliation":[{"name":"Cancer Research, Sidra Medicine, Doha, Qatar"},{"name":"Department of Internal Medicine and Medical Specialties, University of Genova, Genova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Birnbaum","sequence":"additional","affiliation":[{"name":"Laboratory of Predictive Oncology, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), Institut Paoli-Calmettes, Aix-Marseille Universit\u00e9, INSERM UMR1068, CNRS UMR725, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Mamessier","sequence":"additional","affiliation":[{"name":"Laboratory of Predictive Oncology, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), Institut Paoli-Calmettes, Aix-Marseille Universit\u00e9, INSERM UMR1068, CNRS UMR725, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"2025100309054859000_10.1.e003687.1","doi-asserted-by":"crossref","first-page":"iv51","DOI":"10.1093\/annonc\/mdy096","article-title":"Soft tissue and visceral sarcomas: ESMO\u2013EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann Oncol. Elsevier"},{"key":"2025100309054859000_10.1.e003687.2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/annonc\/mdu254","article-title":"Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"25","year":"2014","journal-title":"Ann Oncol"},{"key":"2025100309054859000_10.1.e003687.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.1.350"},{"key":"2025100309054859000_10.1.e003687.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(01)00557-5"},{"key":"2025100309054859000_10.1.e003687.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3141"},{"key":"2025100309054859000_10.1.e003687.6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41698-021-00157-4","article-title":"Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas","volume":"5","author":"Merry","year":"2021","journal-title":"NPJ Precis Oncol"},{"key":"2025100309054859000_10.1.e003687.7","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1673"},{"key":"2025100309054859000_10.1.e003687.8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-8-73"},{"key":"2025100309054859000_10.1.e003687.9","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2174"},{"key":"2025100309054859000_10.1.e003687.10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/annonc\/mdx699","article-title":"The genomic grade index predicts postoperative clinical outcome in patients with soft-tissue sarcoma","volume":"29","author":"Bertucci","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100309054859000_10.1.e003687.11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/annonc\/mdy528","article-title":"Pathological grade-independent prediction of chemosensitivity by CINSARC should rehabilitate adjuvant chemotherapy in soft tissue sarcomas of any grade","volume":"30","author":"Bertucci","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100309054859000_10.1.e003687.12","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.clon.2015.07.004","article-title":"Gene expression signatures as biomarkers of tumour hypoxia","volume":"27","author":"Harris","year":"2015","journal-title":"Clin Oncol"},{"key":"2025100309054859000_10.1.e003687.13","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/bjc.2016.310","article-title":"A prognostic profile of hypoxia-induced genes for localised high-grade soft tissue sarcoma","volume":"115","author":"Aggerholm-Pedersen","year":"2016","journal-title":"Br J Cancer"},{"key":"2025100309054859000_10.1.e003687.14","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.18632\/oncotarget.23280","article-title":"Validation of a hypoxia related gene signature in multiple soft tissue sarcoma cohorts","volume":"9","author":"Yang","year":"2018","journal-title":"Oncotarget"},{"key":"2025100309054859000_10.1.e003687.15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1712"},{"key":"2025100309054859000_10.1.e003687.16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030363","article-title":"The sarcoma immune landscape: emerging challenges, prognostic significance and prospective impact for immunotherapy approaches","volume":"13","author":"Koumarianou","year":"2021","journal-title":"Cancers"},{"key":"2025100309054859000_10.1.e003687.17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020360","article-title":"Immune checkpoint inhibitory therapy in sarcomas: is there light at the end of the tunnel?","volume":"13","author":"Siozopoulou","year":"2021","journal-title":"Cancers"},{"key":"2025100309054859000_10.1.e003687.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.07.008"},{"key":"2025100309054859000_10.1.e003687.19","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-86"},{"key":"2025100309054859000_10.1.e003687.20","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2007-8-8-r157"},{"key":"2025100309054859000_10.1.e003687.21","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2017.1609","article-title":"Development and validation of an individualized immune prognostic signature in early-stage Nonsquamous non-small cell lung cancer","volume":"3","author":"Li","year":"2017","journal-title":"JAMA Oncol"},{"key":"2025100309054859000_10.1.e003687.22","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.19.03205","article-title":"Multicenter International Society for immunotherapy of cancer study of the consensus immunoscore for the prediction of survival and response to chemotherapy in stage III colon cancer","volume":"38","author":"Mlecnik","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100309054859000_10.1.e003687.23","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1253654"},{"key":"2025100309054859000_10.1.e003687.24","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1038\/s41416-018-0309-1","article-title":"The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer","volume":"119","author":"Bertucci","year":"2018","journal-title":"Br J Cancer"},{"key":"2025100309054859000_10.1.e003687.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.10.014"},{"key":"2025100309054859000_10.1.e003687.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1906-8"},{"key":"2025100309054859000_10.1.e003687.27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103131","article-title":"High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies","volume":"62","author":"Toulmonde","year":"2020","journal-title":"EBioMedicine"},{"key":"2025100309054859000_10.1.e003687.28","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-020-02512-8","article-title":"Comprehensive profiling of immune-related genes in soft tissue sarcoma patients","volume":"18","author":"Hu","year":"2020","journal-title":"J Transl Med"},{"key":"2025100309054859000_10.1.e003687.29","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-021-07852-2","article-title":"Development and validation of an immune gene-set based prognostic signature for soft tissue sarcoma","volume":"21","author":"Shen","year":"2021","journal-title":"BMC Cancer"},{"key":"2025100309054859000_10.1.e003687.30","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.620705","article-title":"Identification of tumor microenvironment-related prognostic genes in sarcoma","volume":"12","author":"Dai","year":"2021","journal-title":"Front Genet"},{"key":"2025100309054859000_10.1.e003687.31","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1699"},{"key":"2025100309054859000_10.1.e003687.32","doi-asserted-by":"publisher","DOI":"10.1038\/ng.619"},{"key":"2025100309054859000_10.1.e003687.33","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.381"},{"key":"2025100309054859000_10.1.e003687.34","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4078"},{"key":"2025100309054859000_10.1.e003687.35","doi-asserted-by":"publisher","DOI":"10.1002\/path.2787"},{"key":"2025100309054859000_10.1.e003687.36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3588"},{"key":"2025100309054859000_10.1.e003687.37","doi-asserted-by":"publisher","DOI":"10.1002\/path.2715"},{"key":"2025100309054859000_10.1.e003687.38","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2005-6-9-r76"},{"key":"2025100309054859000_10.1.e003687.39","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800794"},{"key":"2025100309054859000_10.1.e003687.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08270-3"},{"key":"2025100309054859000_10.1.e003687.41","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2013-14-12-r137"},{"key":"2025100309054859000_10.1.e003687.42","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1002\/cncr.26733","article-title":"Gene expression identifies heterogeneity of metastatic propensity in high-grade soft tissue sarcomas","volume":"118","author":"Skubitz","year":"2012","journal-title":"Cancer"},{"key":"2025100309054859000_10.1.e003687.43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.0030187"},{"key":"2025100309054859000_10.1.e003687.44","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25594"},{"key":"2025100309054859000_10.1.e003687.45","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.canlet.2014.09.014","article-title":"EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer","volume":"355","author":"Bertucci","year":"2014","journal-title":"Cancer Lett"},{"key":"2025100309054859000_10.1.e003687.46","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0912708107"},{"key":"2025100309054859000_10.1.e003687.47","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2025100309054859000_10.1.e003687.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2011.03.007"},{"key":"2025100309054859000_10.1.e003687.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2013.10.003"},{"key":"2025100309054859000_10.1.e003687.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.12.033"},{"key":"2025100309054859000_10.1.e003687.51","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000974","article-title":"Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma","volume":"8","author":"Thompson","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100309054859000_10.1.e003687.52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0506580102"},{"key":"2025100309054859000_10.1.e003687.53","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3576"},{"key":"2025100309054859000_10.1.e003687.54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014611"},{"key":"2025100309054859000_10.1.e003687.55","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1712"},{"key":"2025100309054859000_10.1.e003687.56","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.637"},{"key":"2025100309054859000_10.1.e003687.57","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0b013e3181d26d5e"},{"key":"2025100309054859000_10.1.e003687.58","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1278100","article-title":"PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas","volume":"6","author":"Bertucci","year":"2017","journal-title":"Oncoimmunology"},{"key":"2025100309054859000_10.1.e003687.59","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1792036","article-title":"Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma","volume":"9","author":"Dufresne","year":"2020","journal-title":"Oncoimmunology"},{"key":"2025100309054859000_10.1.e003687.60","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19917-0","article-title":"Single cell analysis reveals distinct immune landscapes in transplant and primary sarcomas that determine response or resistance to immunotherapy","volume":"17","author":"Wisdom","year":"2020","journal-title":"Nat Commun"},{"key":"2025100309054859000_10.1.e003687.61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1370"},{"key":"2025100309054859000_10.1.e003687.62","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/JCO.20.03007","article-title":"Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to Individualize prognosis and prediction of chemotherapy benefit in early breast cancer","volume":"39","author":"Sparano","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025100309054859000_10.1.e003687.63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.06.006"},{"key":"2025100309054859000_10.1.e003687.64","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S1470-2045(16)30507-1","article-title":"Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Mir","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025100309054859000_10.1.e003687.65","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21083018","article-title":"CDKs in sarcoma: mediators of disease and emerging therapeutic targets","volume":"21","author":"Kohlmeyer","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025100309054859000_10.1.e003687.66","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12103058","article-title":"Novel therapeutic insights in dedifferentiated liposarcoma: a role for FGFR and MDM2 dual targeting","volume":"12","author":"Dadone-Montaudi\u00e9","year":"2020","journal-title":"Cancers"},{"key":"2025100309054859000_10.1.e003687.67","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-42300-z","article-title":"Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells","volume":"9","author":"Hayasaka","year":"2019","journal-title":"Sci Rep"},{"key":"2025100309054859000_10.1.e003687.68","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0711"},{"key":"2025100309054859000_10.1.e003687.69","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1093\/annonc\/mdy194","article-title":"Validation of the complexity index in sarcomas prognostic signature on formalin-fixed, paraffin-embedded, soft-tissue sarcomas","volume":"29","author":"Le Guellec","year":"2018","journal-title":"Ann Oncol"},{"key":"2025100309054859000_10.1.e003687.70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000617","article-title":"Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response","volume":"8","author":"Roelands","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2021-003687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:05:55Z","timestamp":1759507555000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2021-003687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,10]]},"published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1136\/jitc-2021-003687"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2021-003687","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741507211.793591240","asserted-by":"object"}]},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}